natgillin/translations-raw huggingface dataset:
The lopinavir mean steadystate AUC, Cmax, and Cmin were 72.6 ± 31.1 µg•h/ml, 8.2 ± 2.9 µg/ml and 3.4 ± 2.1 µg/ml, respectively after Kaletra oral solution 230/57.5 mg/m2 twice daily without nevirapine (n=12), and were 85.8 ± 36.9 µg•h/ml, 10.0 ± 3.3 µg/ml and 3.6 ± 3.5 µg/ml, respectively after 300/75 mg/m2 twice daily with nevirapine (n=12). 
3,4 ± 2,1 µg/ml po peroralni raztopini zdravila Kaletra 230/57,5 mg/m2 dvakrat na dan brez nevirapina (n = 12) ter 85,8 ± 36,9 µg•h/ml, 10,0 ± 3,3 µg/ml in 3,6 ± 3,5 µg/ml po 300/75 mg/m2 dvakrat na dan z nevirapinom (n = 12).
Myalgia, musculoskeletal pain including arthralgia and back pain, muscle disorders such as weakness and spasms 
Bolezni mišično-skeletnega sistema in vezivnega tkiva pogosti mialgija, mišično-skeletne bolečine vključno z artralgijo in bolečinami v hrbtu, bolezni mišic kot je šibkost in krči občasni rabdomioliza, osteonekroza
Caution should be exercised in administering afatinib with Kaletra. 
Pri uporabi afatiniba z zdravilom Kaletra je potrebna previdnost.
Increased plasma concentrations of cisapride. 
Večja koncentracija cisaprida v plazmi.
Table 6 
Preglednica 6
The 230/57.5 mg/m2 twice daily regimen without nevirapine and the 300/75 mg/m2 twice daily regimen with nevirapine provided lopinavir plasma concentrations similar to those obtained in adult patients receiving the 400/100 mg twice daily regimen without nevirapine. 
Shemi 230/57,5 mg/m2 dvakrat na dan brez nevirapina in 300/75 mg/m2 dvakrat na dan z nevirapinom sta v plazmi zagotovili koncentracijo lopinavirja, podobno tisti pri odraslih bolnikih, ki so dobivali zdravilo po shemi 400/100 mg dvakrat na dan brez nevirapina.
Alcohol, high fructose corn syrup, propylene glycol, purified water, glycerol, povidone, magnasweet110 flavour (mixture of monoammonium glycyrrhizinate and glycerol), vanilla flavour (containing p-hydroxybenzoic acid, p-hydroxybenzaldehyde, vanillic acid, vanillin, heliotropin, ethyl vanillin), polyoxyl 40 hydrogenated castor oil, cotton candy flavour (containing ethyl maltol, ethyl vanillin, acetoin, dihydrocoumarin, propylene glycol), acesulfame potassium, saccharin sodium, sodium chloride, peppermint oil, sodium citrate, citric acid, levomenthol. 
prečiščeno vodo glicerol povidon aromo Magnasweet-110 (mešanica monoamonijevega glicirizinata in glicerola) aromo vanilije (vsebuje p-hidroksibenzojsko kislino, p-hidroksibenzaldehid, vanilinsko kislino, vanilin, heliotropin, etilvanilin) makrogolglicerol 40 hidrogenirano ricinusovo olje aromo sladkorne pene (vsebuje etilmaltol, etilvanilin, acetoin, dihidrokumarin, propilenglikol) kalijev acesulfamat natrijev saharinat natrijev klorid eterično olje poprove mete natrijev citrat citronsko kislino levomentol
The maximum mean (95% upper confidence bound) differences in QTcF from placebo were 3.6 (6.3) and 13.1(15.8) for 400/100 mg twice daily and supratherapeutic 800/200 mg twice daily LPV/r, respectively. 
Največja povprečna razlika (95 % zgornja meja zaupanja) QTcF v primerjavi s placebom je bila 3,6 (6,3) med uporabo lopinavirja/ritonavirja 400/100 mg dvakrat na dan in 13,1 (15,8) med uporabo supraterapevtskega odmerka lopinavirja/ritonavirja 800/200 mg dvakrat na dan. K podaljšanju intervala QT pripomore podaljšanje intervala QRS s 6 ms na 9,5 ms, ki ga povzročijo veliki odmerki lopinavirja/ritonavirja (800/200 mg dvakrat na dan).
However, dialysis can remove both alcohol and propylene glycol in the case of overdose with Kaletra oral solution. 
Vendar pa lahko v primeru prevelikega odmerjanja zdravila Kaletra peroralna raztopina dializa odstrani tako alkohol kot propilenglikol.
(see Other medicines and Kaletra section); 
(glejte poglavje Druga zdravila in zdravilo
Cmax: ↑ 4.7-fold Due to CYP3A inhibition by lopinavir/ritonavir. 
Cmax: ↑ 4,7-krat zaradi zavrtja CYP3A z lopinavirjem/ritonavirjem.
Fosamprenavir/ ritonavir (700/100 mg 
Fosamprenavir/ ritonavir (700/100 mg dvakrat na dan)
Caution should be exercised and reduced doses should be considered when Kaletra is co-administered with rosuvastatin (see section 4.4). 
Potrebna je previdnost in med sočasno uporabo zdravila Kaletra in rosuvastatina pride v poštev uporaba manjših odmerkov (glejte poglavje 4.4).
Co-administration of Kaletra with rifampicin is not recommended. 
Sočasna uporaba zdravila Kaletra in rifampicina ni priporočljiva.
Take care when dosing children. 
Odmerjanje pri otrocih zahteva previdnost.
Concomitant Therapy: Efavirenz or nevirapine The following table contains dosing guidelines for Kaletra tablets based on BSA when used in combination with efavirenz or nevirapine in children. 
Brez sočasnega zdravljenja z efavirenzom ali nevirapinom Naslednji tabeli vsebujeta smernice za odmerjanje zdravila Kaletra peroralna raztopina na osnovi telesne mase in indeksa telesne mase (ITM).
The pharmacokinetics of Kaletra 100/25 mg tablet twice-daily weight-band dosing without nevirapine have been studied in a total of 53 paediatric patients. 
100/25 mg tablete dvakrat na dan z odmerjanjem glede na telesno maso brez nevirapina so raziskali pri skupaj 53 pediatričnih bolnikih.
Clinical monitoring of antiviral efficacy is recommended when these medicines are concomitantly administered with Kaletra. 
Med uporabo teh zdravil z zdravilom Kaletra je priporočljiv kliničen nadzor protivirusne učinkovitosti.
At entry, median (range) HIV-1 RNA was 6.0 (4.7-7.2) log10 copies/ml and median (range) CD4+T-cell percentage was 
Ob vključitvi je bila mediana (razpon) HIV-1 RNA 6,0 (4,7-7,2) log10 kopij/ml in mediana odstotka (razpon) T-celic CD4 41 (16-59).
Due to CYP3A and P-gp inhibition by lopinavir/ritonavir. 
Zaradi zavrtja CYP3A in P-gp z lopinavirjem/ritonavirjem.
Total amounts of alcohol and propylene glycol from all medicines that are to be given to infants should be taken into account in order to avoid toxicity from these excipients. 
Da bi se izognili toksičnosti pomožnih snovi alkohola in propilenglikola, je treba upoštevati celotno količino alkohola in propilenglikola v vseh zdravilih, danih dojenčku.
Rivaroxaban (Ritonavir 600 mg twice daily) 
Rivaroksaban (Ritonavir 600 mg dvakrat na dan)
Table 7 
Preglednica 7
Concomitant administration of elbasvir/grazoprevir with Kaletra is contraindicated (see section 
Sočasna uporaba elbasvirja/grazoprevirja in zdravila Kaletra je kontraindicirana (glejte poglavje
At the recommended adult dose(s) of this medicine, the estimated blood alcohol concentration in your body is about 0.002 - 0.01 g/dL. 
Pri priporočenih odmerkih tega zdravila za odrasle je ocenjena koncentracija alkohola v krvi približno
The twice-daily weight-band dosing without nevirapine provided lopinavir plasma concentrations similar to those obtained in adult patients receiving the 400/100 mg twice-daily regimen without nevirapine. 
Dvakrat dnevno odmerjenje glede na telesno maso brez nevirapina je v plazmi zagotovilo koncentracijo lopinavirja, podobno tisti pri odraslih bolnikih, ki so dobivali zdravilo po shemi 400/100 mg dvakrat na dan brez nevirapina.
Blood glucose disorders including diabetes mellitus, hypertriglyceridaemia, hypercholesterolemia, weight decreased, decreased appetite 
Presnovne in prehranske motnje pogosti motnje glukoze v krvi vključno s sladkorno boleznijo, hipertrigliceridemija, hiperholesterolemija, znižanje telesne mase, zmanjšan apetit občasni zvišanje telesne mase, zvečan apetit
Patients were randomised to either 230 mg lopinavir/57.5 mg ritonavir per m2 or 300 mg lopinavir/75 mg ritonavir per m2. Naïve patients also received nucleoside reverse transcriptase inhibitors. 
Bolnike so randomizirali bodisi na 230 mg lopinavirja/57,5 mg ritonavirja na m2 ali 300 mg lopinavirja/75 mg ritonavirja na m2.
Increased monitoring for rifabutin-associated adverse reactions including neutropenia and uveitis is warranted due to an expected increase in exposure to rifabutin. 
Zaradi pričakovane povečane izpostavljenosti rifabutinu je upravičen povečan nadzor z rifabutinom povezanih neželenih učinkov, vključno z nevtropenijo in uveitisom.
Co-administration of encorafenib with Kaletra may increase encorafenib exposure which may increase the risk of toxicity, including the risk of serious adverse events such as QT interval prolongation. 
Sočasna uporaba enkorafeniba z zdravilom Kaletra lahko poveča izpostavljenost enkorafenibu, kar lahko poveča tveganje za toksičnost, vključno s tveganjem pojava resnih neželenih učinkov,
Recommended lopinavir/ritonavir dosing (mg) twice daily. 
Priporočeni odmerki lopinavirja/ritonavirja (mg) dvakrat na dan.
Cases of pancreatitis have been reported in patients receiving Kaletra, including those who developed hypertriglyceridaemia. 
Pri bolnikih, ki so dobivali zdravilo Kaletra (vključno s tistimi, pri katerih se je razvila hipertrigliceridemija), so bili opisani primeri pankreatitisa.
Sustained virological response to Kaletra (in combination with nucleoside/nucleotide reverse transcriptase inhibitors) has been also observed in a small Phase II study (M97-720) through 360 weeks of treatment. 
Dolgotrajni virološki odziv na zdravilo Kaletra (v kombinaciji z nukleozidnimi/nukleotidnimi zaviralci reverzne transkriptaze) so ugotovili tudi v majhni študiji II.
For children 2 weeks or older and weighing up to 15 kg 
Za otroke, starejše od 2 tednov, ki tehtajo do15 kg.
Thereby, increasing the risk of serious haematologic abnormalities, or other serious adverse effects from this agent (see section 4.5). 
Zaradi tega večje tveganje za resne hematološke nepravilnosti ali druge resne neželene učinke tega zdravila (glejte poglavje 4.5).
The concomitant administration with alfuzosin is contraindicated (see section 4.5). 
Sočasna uporaba z alfuzosinom je kontraindicirana (glejte poglavje 4.5).
Caution should be exercised in administering carbamazepine or phenobarbital with Kaletra. 
Pri uporabi karbamazepina ali fenobarbitala z zdravilom Kaletra je potrebna previdnost.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING Oral Solution - Bottle label 
PODATKI NA PRIMARNI OVOJNINI Peroralna raztopina - nalepka na plastenki
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Oral solution - Carton containing 300 ml (5 bottles x 60 ml) oral solution 
PODATKI NA ZUNANJI OVOJNINI Peroralna raztopina - škatla, ki vsebuje 300 ml (5 plastenk po 60 ml) peroralne raztopine
No dose adjustment necessary. 
Prilagoditev odmerka ni potrebna.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment should be considered. 
je treba razmisliti o prekinitvi ali opustitvi zdravljenja.
AUC: ↑ 3-fold Cmax: ↑ 1.8-fold 
AUC: ↑ 3-krat Cmax: ↑ 1,8-krat
Interactions with medicinal products 
PROMET Z ZDRAVILOM
Increased plasma concentrations of avanafil (see sections 4.4 and 4.5). 
Zvišane plazemske koncentracije avanafila (glejte poglavji 4.4 in 4.5).
Caution must also be exercised and reduced doses should be considered if Kaletra is used concurrently with rosuvastatin. 
Previdnost je potrebna tudi pri hkratni uporabi zdravila Kaletra z rosuvastatinom; razmisliti je treba o zmanjšanju odmerkov.
This may cause nausea, vomiting, colic, severe purgation at high doses. 
Ta lahko v velikih odmerkih povzroči občutek siljenja na bruhanje, bruhanje, črevesne krče in močan odvajalen učinek.
300 ml (5 bottles x 60 ml) oral solution with five 5 ml oral dosing syringes. 
300 ml (5 plastenk po 60 ml) peroralne raztopine s petimi 5 ml brizgami za peroralno dajanje
• anti-gout medicines (e.g. colchicine). 
- zdravila za zdravljenje protina (npr. kolhicin).
CYP3A4 inhibition likely due to lopinavir/ritonavir. 
Zavrtje CYP3A4 je verjetno zaradi lopinavirja/ritonavirja.
A more pronounced effect on bedaquiline plasma exposures may be observed during prolonged co-administration with lopinavir/ritonavir. 
Cmax: ↔ Bolj izrazit učinek na koncentracijo bedakilina v plazmi se lahko opazi med podaljšano sočasno uporabo z lopinavirjem/ritonavirjem.
Table 4 
Preglednica 4
Each film-coated tablet contains 100 mg of lopinavir co-formulated with 25 mg of ritonavir as a pharmacokinetic enhancer. 
Ena filmsko obložena tableta vsebuje 100 mg lopinavirja, koformuliranega s 25 mg ritonavirja kot farmakokinetičnim stopnjevalcem.
Protocol defined non-inferiority of once-daily dosing compared with twice-daily dosing was demonstrated if the lower bound of the 95% confidence interval for the difference in proportion of subjects responding (once daily minus twice daily) excluded -12% at Week 48. 
Pri 95% spodnji meji zaupanja za razliko pri deležu bolnikov, ki so se odzvali (enkrat dnevno minus dvakrat dnevno), izključujoč -12 % v 48. tednu, je bilo enkrat dnevno odmerjanje v primerjavi z dvakrat dnevnim odmerjanjem neinferiorno kot definirano po protokolu.
Increased plasma concentrations of lovastatin and simvastatin; thereby, increasing the risk of myopathy including rhabdomyolysis (see section 4.5). 
Večje koncentracije lovastatina in simvastatina v plazmi; zaradi tega večje tveganje za miopatijo, vključno z rabdomiolizo (glejte poglavje 4.5).
Increased creatine phosphokinase (CPK), myalgia, myositis, and rarely, rhabdomyolysis have been reported with protease inhibitors, particularly in combination with nucleoside reverse transcriptase inhibitors. 
Med uporabo zaviralcev proteaz so, zlasti v kombinaciji z nukleozidnimi zaviralci reverzne transkriptaze, poročali o zvišanju kreatin fosfokinaze (CPK), mialgiji, miozitisu in, redko, rabdomiolizi.
The combination of Kaletra with atorvastatin is not recommended. 
Uporaba zdravila Kaletra v kombinaciji z atorvastatinom ni priporočljiva.
Lopinavir/ritonavir medicinal product level decreased 
Znižanje koncentracije zdravila z lopinavirjem/ritonavirjem
• Kaletra contains the active substances lopinavir and ritonavir. 
Zdravilo Kaletra vsebuje zdravilni učinkovini lopinavir in ritonavir.
Colloidal anhydrous silica, copovidone, sodium stearyl fumarate, sorbitan laurate. 
Koloidni brezvodni silicijev dioksid, kopovidon, natrijev stearilfumarat, sorbitan lavrat.
Each film-coated tablet contains 200 mg of lopinavir co-formulated with 50 mg of ritonavir as a pharmacokinetic enhancer. 
Ena filmsko obložena tableta vsebuje 200 mg lopinavirja, koformuliranega s 50 mg ritonavirja kot farmakokinetičnim stopnjevalcem.
Amiodarone, Dronedarone Amiodarone, Dronedarone: Concentrations may be increased due to CYP3A4 inhibition by lopinavir/ritonavir. 
Amiodaron, dronedaron Amiodaron, dronedaron: zaradi zavrtja CYP3A z lopinavirjem/ritonavirjem se koncentracija lahko zviša.
Kaletra contains lopinavir and ritonavir, both of which are inhibitors of the P450 isoform CYP3A in vitro. 
Zdravilo Kaletra vsebuje lopinavir in ritonavir, ki in vitro oba zavirata izoobliko CYP3A P450.
Fusidic Acid 
Fusidna kislina
Study P1030 was an open-label, dose-finding trial evaluating the pharmacokinetic profile, tolerability, safety and efficacy of Kaletra oral solution at a dose of 300 mg lopinavir/75 mg ritonavir per m2 twice daily plus 2 NRTIs in HIV-1 infected infants ≥ 14 days and < 6 months of age. 
*analiza z namenom zdravljenja, pri kateri so bili bolniki z manjkajočimi podatki obravnavani kot virološki neuspeh Študija P1030 je bilo odprto preskušanje za določanje odmerka, ki je ocenjevalo farmakokinetični profil, prenašanje ter varnost in učinkovitost zdravila Kaletra peroralna raztopina v odmerku 300 mg lopinavirja/75 mg ritonavirja na m2 dvakrat na dan, ter dveh nukleotidnih in nukleozidnih zaviralcev reverzne transkriptaze pri dojenčkih, okuženih s HIV-1, starih ≥ 14 dni in < 6 mesecev.
The pharmacokinetics of Kaletra 300/75 mg/m2 twice daily with nevirapine and 230/57.5 mg/ m2 twice daily alone have been studied in 53 paediatric patients ranging in age from 6 months to 12 years. 
Farmakokinetika zdravila Kaletra 300/75 mg/m2 dvakrat na dan z nevirapinom in 230/57,5 mg/m2 dvakrat na dan samostojno je bila raziskana pri 53 pediatričnih bolnikih, starih od
• fusidic acid (used to treat skin infections caused by Staphylococcus bacteria such as impetigo and infected dermatitis). 
Staphylococcus); takšni okužbi sta npr. impetigo in okuženi dermatitis.
Paediatric dosing guidelines with concomitant efavirenz or nevirapine 
Smernice za pediatrično odmerjanje pri sočasni uporabi efavirenza ali nevirapina
Copovidone, sorbitan laurate, colloidal anhydrous silica, sodium stearyl fumarate. 
Kopovidon, sorbitan lavrat, koloidni brezvodni silicijev dioksid, natrijev stearilfumarat.
(Lopinavir/ritonavir 400/100 mg BID, multiple dose) 
(Lopinavir/ritonavir 400/100 mg dvakrat na dan, večkratni odmerek)
Erectile dysfunction, menstrual disordersamenorrhoea, menorrhagia 
Motnje reprodukcije in dojk pogosti erektilna disfunkcija, menstrualne motnjeamenoreja, menoragija
It is important that Kaletra tablets are swallowed whole and not chewed, broken or crushed. 
Pomembno je, da tablete zdravila Kaletra zaužijete cele in jih ne žvečite, ne lomite in ne drobite.
A series of blood samples were collected pre-dose and at intervals over the course of 12 hours in trimester 2 and trimester 3, at birth, and 4-6 weeks postpartum (in women who continued treatment post-delivery) for pharmacokinetic analysis of total and unbound levels of plasma lopinavir concentrations. 
Za farmakokinetične analize plazemske koncentracije celokupnega in nevezanega lopinavirja so zbirali serijo krvnih vzorcev pred odmerki in v intervalih po preteku 12 ur v drugem in tretjem trimesečju, ob porodu in 4-6 tednov po porodu (pri ženskah, ki so nadaljevanje z zdravljenjem po porodu).
The concomitant administration of Kaletra and ranolazine is contraindicated (see section 4.3). 
Sočasna uporaba zdravila Kaletra in ranolazina je kontraindicirana (glejte poglavje 4.3).
Multipack: 360 (3 bottles of 120) film-coated tablets 3 month pack 
Multipakiranje: 360 (3 plastenke po 120) filmsko-obloženih tablet
• It is important to keep Kaletra in the bottle it came in and replace the bottle cap after each dose. 
- Pomembno je, da zdravilo Kaletra shranjujete v originalni plastenki in zaporko namestite po vsakem odmerku.
Delamanid (100 mg BID) 
Delamanid (100 mg dvakrat na dan)
Kaletra pharmacokinetics have not been studied in older people. 
Spol, rasa in starost Farmakokinetika zdravila Kaletra pri starejših ljudeh ni raziskana.
• enlargement of the lymph nodes; 
- povečanje limfnih vozlov;
Caution is warranted and therapeutic drug monitoring of digoxin concentrations, if available, is recommended in case of co-administration of Kaletra and digoxin. 
Priporočljiva je terapevtska kontrola koncentracije digoksina, če ta možnost obstaja.
Etravirine (Lopinavir/ritonavir tablet 400/100 mg BID) 
Etravirin (Lopinavir/ritonavir tableta 400/100 mg dvakrat na dan)
Ombitasvir/paritaprevir/ritonavir with or without dasabuvir 
Ombitasvir/paritaprevir/ritonavir z ali brez dasabuvirja
Lopinavir/ritonavir 400/100 mg BID 
Lopinavir/ritonavir 400/100 mg 2x dnevno
Antiretroviral Agents 
Protiretrovirusna zdravila
• mouth sores or ulcerations, inflammation of the stomach and intestine; 
- bolečine ali razjede v ustih, vnetje želodca in črevesa;
• If the dose is up to 2 ml - use the 2 ml oral dosing syringe to prepare a dose. 
- Če je odmerek do 2 ml, za pripravo odmerka uporabite 2 ml brizgo za peroralno dajanje.
For smaller volumes an alternative pack is available. 
Za volumne večje od 2 ml. Za manjše volumne je na voljo drugo pakiranje.
Kaletra tablets are administered orally and must be swallowed whole and not chewed, broken or crushed. 
Tablete zdravila Kaletra se uporabljajo peroralno in jih je treba pogoltniti cele; ne sme se jih gristi, lomiti ali drobiti.
AUC: ↔ Cmin: ↑ 3.5-fold Cmax: ↓ 
AUC: ↔ Cmin: ↑ 3,5-krat Cmax: ↓
It is important to note that cases of pancreatitis have been reported in patients receiving Kaletra, including those who developed hypertriglyceridaemia. 
Omeniti je treba, da so opisani primeri pankreatitisa pri bolnikih, ki so dobivali zdravilo Kaletra,
Age ≥ 6 months to < 12 years cohort (N = 53): 
Kohorta, v kateri je bila starost ≥ 6 tednov do < 6 mesecev (N = 18): Kohorta, v kateri je bila starost ≥ 6 mesecev do < 12 tednov (N = 53):
No dose adjustment is needed for Kaletra. 
Za zdravilo Kaletra odmerka ni treba prilagajati.
This medicinal product contains up to 0.8 g of fructose per dose when taken according to the dosage recommendations. 
To zdravilo, uporabljeno skladno z navodili za odmerjanje, vsebuje do 0,8 g fruktoze na odmerek.
There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthrosis in patients with haemophilia type A and B treated with protease inhibitors. 
Pri bolnikih s hemofilijo tipa A in B, zdravljenih z zaviralci proteaz, so poročali o povečanju krvavitev, vključno s spontanimi kožnimi hematomi in hemartrozami.
Hepatic Insufficiency 
Ledvična insuficienca
• Nausea, vomiting, abdominal pain, difficulty breathing and severe weakness of the muscles in the legs and arms as these symptoms may indicate raised lactic acid levels. 
- Siljenje na bruhanje, bruhanje, bolečine v trebuhu, ker ti simptomi lahko nakazujejo na pankreatitis (vnetje trebušne slinavke).
Outcomes at Week 48: Study M98-940* Antiretroviral Naïve (N=44) 
Rezultati v 48. tednu: Študija M98-940* Bolniki, ki še niso bili zdravljeni s protiretrovirusnimi zdravili (N=44)
Patients taking the oral solution, particularly those with renal impairment or with decreased ability to metabolise propylene glycol (e.g. those of Asian origin), should be monitored for adverse reactions potentially related to propylene glycol toxicity (i.e. seizures, stupor, tachycardia, hyperosmolarity, lactic acidosis, renal toxicity, haemolysis) (see section 4.3). 
Drugo Bolnike, ki uporabljajo peroralno raztopino, zlasti tiste z okvaro ledvic ali slabšo zmožnostjo za presnovo propilenglikola (npr. tiste azijskega porekla), je treba nadzirati glede neželenih učinkov, ki so lahko povezani s toksičnostjo propilenglikola (t.j.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz, 600 mg QD Lopinavir: 
Nenukleozidni zaviralci reverzne transkriptaze (NNRTI) Efavirenz, 600 mg enkrat na dan
Kaletra is also supplied as 100 mg/25 mg film-coated tablets. 
Zdravilo Kaletra je na voljo tudi kot 100 mg/25 mg filmsko obložene tablete.
Uncommon Gastrointestinal haemorrhage including gastrointestinal ulcer, duodenitis, gastritis and rectal haemorrhage, stomatitis and oral ulcers, faecal incontinence, constipation, dry mouth 
bolečine v zgornjem in spodnjem delu trebuha, napihnjenost trebuha, dispepsija, hemoroidi, flatulenca občasni gastrointestinalna hemoragija, vključno z razjedami v prebavilih, duodenitis, gastritis in rektalna hemoragija, stomatitis in razjede v ustih, fekalna inkontinenca, zaprtje, suha usta
Clinical monitoring of therapeutic and adverse effects is recommended when these medicines are concomitantly administered with Kaletra. 
Med uporabo teh zdravil z zdravilom Kaletra je priporočljiv kliničen nadzor terapevtskih in neželenih učinkov.
dosage adjustment recommendations. 
Glejte priporočila za odmerjanje pri odraslih
Concomitant use of sildenafil prescribed for the treatment of pulmonary arterial hypertension with Kaletra is contraindicated (see section 4.3). 
Sočasna uporaba sildenafila za zdravljenje pljučne arterijske hipertenzije in zdravila Kaletra je kontraindicirana (glejte poglavje 4.3).
Median baseline CD4 cell count was 349 cells/mm3 (range 72 to 807 cells/mm3) and median baseline plasma HIV-1 RNA was 4.0 log10 copies/ml (range 2.9 to 5.8 log10 copies/ml). 
Mediano izhodiščno število celic CD4 je bilo 349 celic/mm3 (razpon od 72 do 807 celic/mm3) in mediana izhodiščna HIV-1 RNA v plazmi je bila 4,0 log10 kopij/ml (razpon od 2,9 do 5,8 log10 kopij/ml).
Kaletra oral solution is supplied in amber coloured multiple-dose polyethylene terephthalate (PET) bottles in a 60 ml size. 
Zdravilo Kaletra peroralna raztopina je na voljo v 60 ml plastenkah za večkratno odmerjanje, jantarne barve, izdelane iz polietilentereftalata (PET).
Herbal products St John's wort (Hypericum perforatum) 
Šentjanževka (Hypericum perforatum)
Kaletra contains potassium as acesulfame potassium, which may be harmful to people on a low potassium diet. High potassium in the blood can cause stomach upset and diarrhoea. 
Zdravilo Kaletra vsebuje kalij v obliki kalijevega acesulfamata, kar lahko škoduje ljudem na dieti z malo kalija.